The Community Guide

- gsearch

Search Results

Narrow Results:

2020 1
2018 1
2017 1
2016 2
2014 1
2013 2
2012 1

Journal Article 9

1 - 9 of 9 Results

Refine Results

Refine Results:

Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death

CITE Title : Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death Personal Author(s) : McMahon, Brian J;Bruden, Dana;Townshend-Bulson, Lisa;Simons, Brenna;Spradling, Phillip;Livingston, Stephen;Gove, James;Hewitt, Annette;Plotnik, Julia;Homan, Chriss;Espera, Hannah;Negus, Susan;Snowball, Mary;Barbour, Youssef;Bruce, Michael;Gounder, Prabhu; Published Date : 3 2017;3-2017; Source : Clin Gastroenterol Hepatol. 15(3):431-437.e2 URL : https://stacks.cdc.gov/view/cdc/44267 McMahon, Brian J et al. (2017). Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death. 15(3). McMahon, Brian J et al. "Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death" 15, no. 3 (2017) McMahon, Brian J et al. "Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death" vol. 15, no. 3, 2017 Export RIS Citation Information.

:

McMahon, Brian J ;

Bruden, Dana

3 2017 | Clin Gastroenterol Hepatol. 15(3):431-437.e2

:

Background & AimsFew studies have examined factors associated with disease progression in hepatitis C virus (HCV) infection. We examined the associati...
Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease

CITE Title : Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease Personal Author(s) : McMahon, Brian J;Bulkow, Lisa;Simons, Brenna;Zhang, Yuhong;Negus, Susan;Homan, Chriss;Spradling, Philip;Teshale, Eyasu;Lau, Daryl;Snowball, Mary;Livingston, Stephen; Published Date : 4 2014;4-2014; Source : Clin Gastroenterol Hepatol. 12(4):701-6.e1-3 URL : https://stacks.cdc.gov/view/cdc/35090 McMahon, Brian J et al. (2014). Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease. 12(4). McMahon, Brian J et al. "Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease" 12, no. 4 (2014) McMahon, Brian J et al. "Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease" vol. 12, no. 4, 2014 Export RIS Citation Information.

:

McMahon, Brian J ;

Bulkow, Lisa

4 2014 | Clin Gastroenterol Hepatol. 12(4):701-6.e1-3

:

ConclusionOf participants, 26% met criteria for immune active HBV. An HBV DNA level of > 20,000 IU/ml was strongly correlated with persons meeting the...
H pylori-associated pathologic findings among Alaska native patients

CITE Title : H pylori-associated pathologic findings among Alaska native patients Personal Author(s) : Nolen, Leisha Diane;Bruden, Dana;Miernyk, Karen;McMahon, Brian J;Sacco, Frank;Varner, Wayne;Mezzetti, Tom;Hurlburt, Debby;Tiesinga, James;Bruce, Michael G; Published Date : Dec 2018 Source : Int J Circumpolar Health 2018; 77(1) URL : https://stacks.cdc.gov/view/cdc/59657 Nolen, Leisha Diane et al. (2018). H pylori-associated pathologic findings among Alaska native patients. 77(1). Nolen, Leisha Diane et al. "H pylori-associated pathologic findings among Alaska native patients" 77, no. 1 (2018) Nolen, Leisha Diane et al. "H pylori-associated pathologic findings among Alaska native patients" vol. 77, no. 1, 2018 Export RIS Citation Information.

:

Nolen, Leisha Diane ;

Bruden, Dana

Dec 2018 | Int J Circumpolar Health 2018; 77(1)

:

Helicobacter pylori infection is common among Alaska native (AN) people, however scant gastric histopathologic data is available for this population T...
Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010

CITE Title : Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010 Personal Author(s) : Tohme, Rania A;Bulkow, Lisa;Homan, Chriss E;Negus, Susan;McMahon, Brian J; Published Date : Aug 16 2013 Source : J Clin Virol 58(2):396-400 URL : https://stacks.cdc.gov/view/cdc/35105 Tohme, Rania A et al. (2013). Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010. 58(2). Tohme, Rania A et al. "Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010" 58, no. 2 (2013) Tohme, Rania A et al. "Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B—Alaska, 2001–2010" vol. 58, no. 2, 2013 Export RIS Citation Information.

:

Tohme, Rania A ;

Bulkow, Lisa

Aug 16 2013 | J Clin Virol 58(2):396-400

:

BackgroundA high prevalence of reactivation of hepatitis B has been documented among immunosuppressed individuals in the inactive phase of chronic hep...
Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012

CITE Title : Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012 Personal Author(s) : Gounder, Prabhu P;Bulkow, Lisa R;Meltzer, Martin I;Bruce, Michael G;Hennessy, Thomas W;Snowball, Mary;Spradling, Philip R;Adhikari, Bishwa B;McMahon, Brian J; Published Date : May 18 2016 Source : Int J Circumpolar Health 2016; 75 URL : https://stacks.cdc.gov/view/cdc/39948 Gounder, Prabhu P et al. (2016). Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012. 75 Gounder, Prabhu P et al. "Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012" 75 (2016) Gounder, Prabhu P et al. "Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012" vol. 75, 2016 Export RIS Citation Information.

:

Gounder, Prabhu P ;

Bulkow, Lisa R

May 18 2016 | Int J Circumpolar Health 2016; 75

:

BackgroundThe American Association for the Study of Liver Diseases (AASLD) recommends semi-annual hepatocellular carcinoma (HCC) screening using ultra...
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C

CITE Title : Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C Personal Author(s) : Livingston, Stephen E;Townshend-Bulson, Lisa J;Bruden, Dana J T;Homan, Chriss E;Gove, James E;Plotnik, Julia N;Simons, Brenna C;Spradling, Philip R;McMahon, Brian J; Published Date : Mar 29 2016 Source : Int J Circumpolar Health 2016; 75 URL : https://stacks.cdc.gov/view/cdc/39194 Livingston, Stephen E et al. (2016). Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. 75 Livingston, Stephen E et al. "Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C" 75 (2016) Livingston, Stephen E et al. "Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C" vol. 75, 2016 Export RIS Citation Information.

:

Livingston, Stephen E ;

Townshend-Bulson, Lisa J

Mar 29 2016 | Int J Circumpolar Health 2016; 75

:

BackgroundThere have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populationsObjectiveTo...
Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

CITE Title : Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children Personal Author(s) : Raczniak, Gregory A;Thomas, Timothy K;Bulkow, Lisa R;Negus, Susan E;Zanis, Carolyn L;Bruce, Michael G;Spradling, Philip R;Teshale, Eyasu H;McMahon, Brian J; Published Date : Mar 05 2013 Source : Vaccine 31(17):2152-2155 URL : https://stacks.cdc.gov/view/cdc/36501 Raczniak, Gregory A et al. (2013). Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. 31(17). Raczniak, Gregory A et al. "Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children" 31, no. 17 (2013) Raczniak, Gregory A et al. "Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children" vol. 31, no. 17, 2013 Export RIS Citation Information.

:

Raczniak, Gregory A ;

Thomas, Timothy K

Mar 05 2013 | Vaccine 31(17):2152-2155

:

BackgroundHepatitis A is mostly a self-limiting disease but causes substantial economic burden Consequently, United States Advisory Committee for Immu...
Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care

CITE Title : Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care Personal Author(s) : McMahon, Brian J;Townshend-Bulson, Lisa;Homan, Chriss;Gounder, Prabhu;Barbour, Youssef;Hewitt, Annette;Bruden, Dana;Espera, Hannah;Plotnik, Julia;Gove, James;Stevenson, Timothy J;Luna, Sarah V;Simons, Brenna C; Published Date : Apr 15 2020 Source : Clin Infect Dis 70(9):2005-2007 URL : https://stacks.cdc.gov/view/cdc/85474 McMahon, Brian J et al. (2020). Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care. 70(9). McMahon, Brian J et al. "Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care" 70, no. 9 (2020) McMahon, Brian J et al. "Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care" vol. 70, no. 9, 2020 Export RIS Citation Information.

:

McMahon, Brian J ;

Townshend-Bulson, Lisa

Apr 15 2020 | Clin Infect Dis 70(9):2005-2007

:

Most persons with chronic hepatitis C virus (HCV) infection in the United States are undiagnosed or linked to care We describe a program for the manag...
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection

CITE Title : Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection Personal Author(s) : Livingston, Stephen E;Townshend-Bulson, Lisa J;Bruden, Dana L;McMahon, Brian J;Homan, Chriss E;Gove, James E;Deubner, Heike;Bruce, Michael G;Robinson, Renee F;Gretch, David R; Published Date : Apr 24 2012 Source : Int J Circumpolar Health 2012; 71 URL : https://stacks.cdc.gov/view/cdc/10911 Livingston, Stephen E et al. (2012). Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. 71 Livingston, Stephen E et al. "Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection" 71 (2012) Livingston, Stephen E et al. "Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection" vol. 71, 2012 Export RIS Citation Information.

:

Livingston, Stephen E ;

Townshend-Bulson, Lisa J

Apr 24 2012 | Int J Circumpolar Health 2012; 71

:

ObjectivesTreatment with pegylated interferon and ribavirin may prevent progression of liver disease among patients with chronic hepatitis C virus inf...